CRISPR Therapeutics AG
Price
OptionsOpen the Sheet →FilingsNewest: 10-Q, Quarterly reportAug 3 →InsidersNo open-market buys. 4 insiders sold $16.9M, 10 of 26 sales on a 10b5-1 plan.→Financing →PeersClosest companies: CRBU, BEAM, MGTX→
From the filings
Figures
- Revenue
- $13.4Mlast 12 months
- Net income
- −$451.1Mlast 12 months
- Operating cash flow
- −$400.0Mlast 12 months
- Cash and equivalents
- $291.3Mat the last balance sheet
- Total debt
- $586.2Mat the last balance sheet
- Shares outstanding
- 96.7M shareson issue